儿科耐火性慢性免疫血小板缺血症:识别,患者的特征和结果
Thomas Pincez1,2, Helder Fernandes1,3, Mony Fahd1,4
1Centre de Référence National des Cytopénies Auto-immunes de l'Enfant (CEREVANCE), Bordeaux and Paris, France.
American journal of hematology
|April 23, 2024
概括
在儿童中,耐火性慢性免疫血小板缺血症 (r-cITP) 由于定义不一致而带来挑战. 脊髓切除术可以改善缓解率,而二线治疗有助于预防这些患者严重出血.
科学领域:
- 儿科血液学 儿科血液学
- 免疫学 免疫学 免疫学
- 临床治疗学 临床治疗学
背景情况:
- 耐药性慢性免疫血小板缩症 (r-cITP) 在儿科护理中带来了重大挑战.
- 儿科r-cITP的不一致定义限制了现有的数据和治疗指南.
- 识别和描述r-cITP对于有效管理至关重要.
研究的目的:
- 为了比较儿科r-cITP的各种定义,并描述患者群体.
- 为了确定r-cITP的发病率和临床过程.
- 评估治疗结果,包括缓解率和出血事件.
主要方法:
- 在886名cITP患者中对7个r-cITP定义进行了比较分析,其中包括5个儿科专用定义.
- 多变量分析以确定与r-cITP相关的因素.
- 评估缓解和出血事件的累积发病率,重点关注脊髓切除术的结果.
主要成果:
- 儿科定义确定了重叠的患者群 (4%-20%) 具有更高的免疫病理表现 (IM) 和全身性红斑狼 (SLE) 发病率.
- 根据CEREVANCE的定义,确定了79名r-cITP患者;发病率为每年1.15%的新患者,随年龄增长而增加.
- 切除术与持续完全缓解 (CCR) 的累积发病率显著更高 (HR:5.43). 第二线治疗在预防严重出血方面显得有效.
结论:
- 儿科r-cITP患者患有IM和SLE的风险增加,无论使用什么定义.
- r-cITP可以在任何随访时间发生,而年龄较大是一个危险因素.
- 切除术可以增强CCR,二线治疗对于预防严重出血至关重要.
更多相关视频
09:46Megakaryocyte Differentiation and Platelet Formation from Human Cord Blood-derived CD34+ Cells
Published on: December 27, 2017
19.7K
11:59Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies
Published on: September 6, 2017
7.3K
相关概念视频
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...